<DOC>
	<DOC>NCT01227668</DOC>
	<brief_summary>The purpose of this study is to determine whether pediatric participants with irritability associated with autistic disorder who have responded to aripiprazole treatment will experience a relapse significantly later when continuing therapy with aripiprazole than will participants who receive placebo</brief_summary>
	<brief_title>Phase IV Long-term Maintenance Study of Aripiprazole in the Treatment of Irritability Associated With Autistic Disorder</brief_title>
	<detailed_description>Phase 1: Single blind/ Phase 2: Double blind</detailed_description>
	<mesh_term>Disease</mesh_term>
	<mesh_term>Autistic Disorder</mesh_term>
	<mesh_term>Aripiprazole</mesh_term>
	<criteria>Key Male or female children or adolescents, 6 to 17 years of age, inclusive, at the time of the baseline visit Meets current diagnostic criteria of the Diagnostic and Statistical Manualof Mental Disorders IVText Revised for autistic disorder and displays behaviors such as tantrums, aggression, selfinjurious behavior, or a combination of these problems. Diagnosis of autistic disorder will be confirmed by the Autism Diagnostic InterviewRevised. Participant or designated guardian or caregiver is able to comprehend and satisfactorily comply with the protocol requirements, in the opinion of the investigator. Demonstrates behaviors such as tantrums, aggression, or selfinjury or a combination of these problems An Aberrant Behavior Checklist Irritability subscale score ≥18 AND a Clinical Global Impressions Severity score ≥4 at the Screening and Baseline Visits. Mental age of at least 24 months Key Treatment resistant to neuroleptic medication, based on lack of therapeutic response to 2 different neuroleptics after treatment for at least 3 weeks each. Previous treatment with aripiprazole for at least 3 weeks duration at an adequate daily dose, without demonstrating a clinically meaningful response. Lifetime diagnosis of bipolar disorder, psychosis, or schizophrenia, or a current diagnosis of major depressive disorder Diagnosis of Pervasive Developmental DisorderNot Otherwise Specified, Asperger's Syndrome, Rett's Syndrome, childhood disintegrative disorder, or Fragile X Syndrome History of neuroleptic malignant syndrome At significant risk for suicide based on history or routine psychiatric status examination A seizure within the past year History of severe head trauma or stroke History or current evidence of any unstable medical conditions that would expose the patient to undue risk of a significant adverse event or interfere with assessments of safety or efficacy during the course of the trial Weight lower than 15 kg Known allergy or hypersensitivity to aripiprazole or other dihidrocarbostyrils History of a clinically significant low white blood cell count or a druginduced leukopenia/neutropenia Any other medically significant abnormal laboratory test or vital sign result or electrocardiogram finding</criteria>
	<gender>All</gender>
	<minimum_age>6 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>March 2014</verification_date>
</DOC>